1) Strategic Focus and Leadership Updates
- Baxter's leadership emphasizes a turnaround strategy, focusing on execution and operational improvements across all segments.
- The company is consolidating its Pharmaceuticals and Infusion Therapies & Technologies businesses under a new division, Infusion Therapies & Platforms (ITP), to enhance coordination and innovation.
- The Baxter Growth & Performance System (GPS) is being embedded into the company culture, with over 400 continuous improvement events completed in the first half of the year.

2) Financial Performance and Segment Results
- Q2 2026 global sales reached approximately $3 billion, reflecting a 5% increase both reported and organically.
- Adjusted earnings per share (EPS) were $0.56, down from $0.59 YoY, impacted by mechanical headwinds but benefitting from a $75 million tariff refund contributing $0.11 per share.
- Key segment performances:
| Segment | Q2 Sales (in millions) | Organic Growth (%) | |-------------------------------|------------------------|--------------------| | Medical Products & Therapy | $2,100 | 5 | | Infusion Therapies & Platforms | $1,700 | 4 | | Advanced Surgery | $331 | 12 | | Healthcare Systems & Technologies | $801 | 4 |

3) Challenges and Headwinds
- Ongoing supply chain challenges, particularly with contract manufacturers affecting the injectables and anesthesia segments.
- The Novum IQ LVP product remains under regulatory scrutiny, with no material impact from returns observed in Q2, but uncertainty persists regarding its market re-entry.
- The company faces inflationary pressures and tariff impacts, with expectations of approximately $40 million in tariff-related costs in the second half of the year.

4) Operational and Product Development Plans
- Continued investment in innovation, including the launch of PeerVue, a digital benchmarking application, and the Vest APX Acute Care device, which has received positive initial feedback.
- Strong demand is noted for the Connex 360 connected patient monitoring platform and the Dynamo smart hospital stretcher, with expansion into international markets.
- The company aims to improve supply reliability and operational efficiency, particularly in the pharmaceutical portfolio.

5) Guidance and Outlook
- Baxter raised its full-year organic sales growth outlook to 2% to 3% and adjusted EPS guidance to $1.95 to $2.15 per diluted share, reflecting confidence in the second half of the year.
- The company expects to achieve a net leverage target of approximately 3x by year-end, which would enhance its financial flexibility for potential M&A and capital returns.
- The transcript lacks specific details on the anticipated impact of regulatory changes and macroeconomic factors on future performance.

Bottom line: Baxter's Q2 results show solid progress in its turnaround strategy, with strong organic growth and operational improvements. However, ongoing challenges in supply chain and regulatory compliance remain. The raised guidance reflects confidence in continued momentum, positioning the company for sustainable growth and shareholder value creation.